MA53238A - Formules d'ag10 - Google Patents

Formules d'ag10

Info

Publication number
MA53238A
MA53238A MA053238A MA53238A MA53238A MA 53238 A MA53238 A MA 53238A MA 053238 A MA053238 A MA 053238A MA 53238 A MA53238 A MA 53238A MA 53238 A MA53238 A MA 53238A
Authority
MA
Morocco
Prior art keywords
formulas
Prior art date
Application number
MA053238A
Other languages
English (en)
Inventor
Jesper Jernelius
Mark Michael Menning
Original Assignee
Eidos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eidos Therapeutics Inc filed Critical Eidos Therapeutics Inc
Publication of MA53238A publication Critical patent/MA53238A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA053238A 2018-08-17 2019-08-16 Formules d'ag10 MA53238A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862765154P 2018-08-17 2018-08-17

Publications (1)

Publication Number Publication Date
MA53238A true MA53238A (fr) 2022-04-13

Family

ID=69524257

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053238A MA53238A (fr) 2018-08-17 2019-08-16 Formules d'ag10

Country Status (27)

Country Link
US (3) US11260047B2 (fr)
EP (2) EP3836920B1 (fr)
JP (2) JP7469293B2 (fr)
KR (1) KR20210046708A (fr)
CN (1) CN112804998A (fr)
AU (2) AU2019321583C1 (fr)
BR (1) BR112020026493A2 (fr)
CA (1) CA3104695A1 (fr)
CL (1) CL2021000289A1 (fr)
DK (1) DK3836920T3 (fr)
EA (1) EA202190561A1 (fr)
ES (1) ES3055121T3 (fr)
FI (1) FI3836920T3 (fr)
HR (1) HRP20251603T1 (fr)
IL (2) IL280906B1 (fr)
LT (1) LT3836920T (fr)
MA (1) MA53238A (fr)
MX (1) MX2021001761A (fr)
PL (1) PL3836920T3 (fr)
PT (1) PT3836920T (fr)
RS (1) RS67572B1 (fr)
SG (1) SG11202101393PA (fr)
SI (1) SI3836920T1 (fr)
SM (1) SMT202500463T1 (fr)
TW (1) TWI834708B (fr)
UA (1) UA128256C2 (fr)
WO (1) WO2020037189A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116730921A (zh) 2017-02-17 2023-09-12 文涵治疗有限公司 Ag-10的制备方法、其中间体及其盐
MA52137A (fr) 2018-03-23 2021-01-27 Eidos Therapeutics Inc Méthodes de traitement de l'amylose ttr à l'aide d'ag10
JP7469293B2 (ja) 2018-08-17 2024-04-16 エイドス セラピューティクス，インコーポレイティド Ａｇ１０の製剤
WO2023052652A1 (fr) 2021-10-01 2023-04-06 Sandoz Ag Forme cristalline d'acoramidis chlorhydrate
WO2025235883A1 (fr) 2024-05-10 2025-11-13 Eidos Therapeutics, Inc. Acoramidis destiné à être utilisé dans le traitement d'un dysfonctionnement rénal

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4255329A (en) 1973-10-02 1981-03-10 Syva Company Double receptor fluorescent immunoassay
US4117149A (en) 1975-09-12 1978-09-26 Pfizer Inc. 4-oxo-4h-benzopyrans as animal growth promotants
US4261928A (en) 1977-08-05 1981-04-14 Sterling Drug Inc. 2-Benzoyl-8-(2-chloro-4-methoxyphenoxy)-1-phenyl-1-octanone
US4171365A (en) 1977-08-05 1979-10-16 Sterling Drug Inc. Antiviral aryloxyalkylpyrazoles
US4232161A (en) 1979-10-24 1980-11-04 Sterling Drug Inc. 4-[6-(2-Chloro-4-methoxyphenoxy)hexyl]-3,5-diethyl-1-(2-pyridinyl)-1H-pyrazole
US4234725A (en) 1979-10-24 1980-11-18 Sterling Drug Inc. 4-[6-(2-Chloro-4-methoxyphenoxy)hexyl]-3,5-diethyl-1-[4-(4-morpholinyl)-1-oxobutyl]-1H-pyrazole
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4668640A (en) 1981-12-11 1987-05-26 Abbott Laboratories Fluorescence polarization immunoassay utilizing substituted carboxyfluoresceins
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
GB2120242A (en) 1982-04-30 1983-11-30 Erba Farmitalia Ergoline derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4764521A (en) 1983-07-18 1988-08-16 Eli Lilly And Company Leukotriene antagonists and a method of use there as
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US5315015A (en) 1992-11-10 1994-05-24 Hoffmann-La Roche Inc. Compounds having improved fluorescence in fluorescence polarization immunoassays and immunoassays utilizing same
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
HU224548B1 (hu) 1993-04-07 2005-10-28 Taiho Pharmaceutical Co. Ltd. Tiazolidinszármazékok és ezeket tartalmazó gyógyszerkészítmények, valamint eljárás előállításukra
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
AU722289B2 (en) 1996-10-01 2000-07-27 Aptalis Pharmatech, Inc. Taste-masked microcapsule compositions and methods of manufacture
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
CN1152673C (zh) 1997-10-28 2004-06-09 坂东化学株式会社 皮肤贴附药片及其基片的制造方法
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
NZ519984A (en) 2000-01-07 2004-03-26 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
JP2005513026A (ja) 2001-11-15 2005-05-12 インサイト サン ディエゴ インコーポレイテッド 高コレステロール血症、異脂肪血症および他の代謝障害；癌、および他の疾患を治療するｎ−置換複素環
SI1511710T1 (sl) 2002-05-31 2014-04-30 Proteotech, Inc. Spojine, sestavki in postopki za zdravljenje amiloidnih bolezni in sinukleinopatij, kot je Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsova bolezen
TW200403061A (en) 2002-06-04 2004-03-01 Glaxo Group Ltd Pharmaceutical compositions
WO2004096808A1 (fr) 2003-04-28 2004-11-11 De Novo Pharmaceuticals Limited Composes de triazine et leur utilisation
US20050113394A1 (en) 2003-11-26 2005-05-26 Wood Allen W. Pharmaceutical compositions
JP4880591B2 (ja) 2004-06-04 2012-02-22 テバ ファーマシューティカル インダストリーズ リミティド イルベサルタンを含む医薬組成物
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
WO2006088694A1 (fr) 2005-02-14 2006-08-24 Wyeth THIÉNYL- ET FURYLACYLGUANIDINE SUBSTITUÉES ET MÉTHODES D'EMPLOI DESDITS COMPOSÉS EN TANT QUE RÉGULATEURS DE LA β-SECRÉTASE
US20070000505A1 (en) 2005-02-24 2007-01-04 Philip Morris Usa Inc. Smoking article with tobacco beads
US20070043097A1 (en) 2005-07-18 2007-02-22 Horizon Therapeutics, Inc. Medicaments containing famotidine and ibuprofen and administration of same
SI1928427T1 (sl) 2005-09-23 2010-03-31 Hoffmann La Roche Nove formulacije za doziranje
EP2102165A2 (fr) 2006-11-24 2009-09-23 AC Immune S.A. Derivés n-(méthyl)-1h-pyrazol-3-amine, n-(methyl)-pyridine-2-amine and n-(methyl)-thiazol-2-amine pour le traitement de maladies associés avec proteins amyloid ou similairs, comme p.e. alzheimer
MX2009006756A (es) 2006-12-22 2009-06-30 Novartis Ag Derivados de 1-amino-metil-l-fenil-ciclohexano como inhibidores de dpp-iv.
PT2155717E (pt) 2007-05-11 2012-12-21 Lilly Co Eli 2-[4-(pirazol-4-ilalquil)piperazin-1-il]-3-fenil-pirazinas e -piridinas e 3-[4-(pirazol-4-ilalquil)piperazin-1-il]-2- fenil-piridinas como antagonistas do recetor 5-ht7
NZ581127A (en) 2007-05-25 2012-06-29 Abbott Gmbh & Co Kg Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
JP5243537B2 (ja) 2007-06-06 2013-07-24 トレント ファーマシューティカルズ リミテッド 新規化合物
SG182187A1 (en) 2007-06-08 2012-07-30 Abbott Gmbh & Co Kg 5-heteroaryl substituted indazoles as kinase inhibitors
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
PT2260020E (pt) 2008-03-26 2014-10-28 Novartis Ag Inibidores das desacetilases b baseados no hidroxamato
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
US8048887B2 (en) 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7994171B2 (en) 2008-09-11 2011-08-09 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
SG10201809460SA (en) 2008-10-20 2018-11-29 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of transthyretin
HRP20180589T1 (hr) 2008-10-28 2018-05-18 Arena Pharmaceuticals, Inc. Pripravci modulatora serotoninskog receptora 5-ht2a koji su korisni za liječenje s njim povezanih poremećaja
US8697685B2 (en) 2008-11-20 2014-04-15 Glaxosmithkline Llc Chemical compounds
EP2488028B1 (fr) 2009-10-14 2020-08-19 Merck Sharp & Dohme Corp. Pipéridines substituées qui accroissent l'activité de p53 et utilisations de ces composés
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
US20110144211A1 (en) 2009-12-11 2011-06-16 Lars Hermann Use of microcrystalline cellulose for interfering with the extraction of ephedrine
BR112012026255A2 (pt) * 2010-04-07 2017-03-14 Vertex Pharma composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas
WO2011140333A1 (fr) 2010-05-07 2011-11-10 The Board Of Trustees Of The Leland Stanford Junior University Identification de stabilisants de protéines multimériques
RU2013132650A (ru) 2010-12-16 2015-01-27 Аллерган, Инк. Серные производные в качестве модуляторов хемокиновых рецепторов
US20140142174A1 (en) 2011-07-07 2014-05-22 Urbain Alfons C. Delaet Darunavir formulations
JP2014526508A (ja) 2011-09-14 2014-10-06 セルジーン コーポレイション シクロプロパンカルボン酸｛２−［（１ｓ）−１−（３−エトキシ−４−メトキシ−フェニル）−２−メタンスルホニル−エチル］−３−オキソ−２，３−ジヒドロ−１ｈ−イソインドール−４−イル｝−アミドの製剤
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
EP3738952A1 (fr) 2014-02-14 2020-11-18 Exelixis, Inc. Formes solides cristallines du n-{4-[(6,7-diméthoxyquinolin-4-yl)oxy]phényl}-n'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide, procédés de préparation et d'utilisation
US20160045609A1 (en) 2014-08-14 2016-02-18 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
HUE047477T2 (hu) 2015-06-04 2020-04-28 Pfizer Palbociclib szilárd dózisformái
EA201792592A1 (ru) 2015-06-30 2018-06-29 Джилид Сайэнс, Инк. Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
UA121775C2 (uk) 2015-07-31 2020-07-27 Пфайзер Інк. 1,1,1-трифтор-3-гідроксипропан-2-ілкарбаматні похідні та 1,1,1-трифтор-4-гідроксибутан-2-ілкарбаматні похідні як інгібітори magl
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
CN116730921A (zh) 2017-02-17 2023-09-12 文涵治疗有限公司 Ag-10的制备方法、其中间体及其盐
EP3675827A1 (fr) 2017-08-30 2020-07-08 Acadia Pharmaceuticals Inc. Formulations de pimavansérine
MA52137A (fr) 2018-03-23 2021-01-27 Eidos Therapeutics Inc Méthodes de traitement de l'amylose ttr à l'aide d'ag10
JP7469293B2 (ja) 2018-08-17 2024-04-16 エイドス セラピューティクス，インコーポレイティド Ａｇ１０の製剤
IL297840A (en) 2020-05-06 2023-01-01 Corcept Therapeutics Inc Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators
CA3201497A1 (fr) 2020-11-11 2022-05-19 Spero Therapeutics, Inc. Formulation de comprime de tebipeneme pivoxil a dosage eleve
US20230330006A1 (en) 2020-12-18 2023-10-19 Amneal Complex Products Rearch LLC Sustained Release Compositions Comprising Liothyronine
WO2024182635A1 (fr) 2023-03-01 2024-09-06 Eidos Therapeutics, Inc. Stabilisation de transthyrétine (ttr) puissante chez des patients atteints d'amyloïdose de ttr recevant de l'acoramidis

Also Published As

Publication number Publication date
EP4647068A2 (fr) 2025-11-12
US20220313661A1 (en) 2022-10-06
EP4647068A3 (fr) 2026-02-25
LT3836920T (lt) 2026-01-26
PT3836920T (pt) 2025-12-02
AU2019321583C1 (en) 2025-11-27
IL280906B1 (en) 2026-01-01
CN112804998A (zh) 2021-05-14
RS67572B1 (sr) 2026-01-30
FI3836920T3 (fi) 2025-12-22
AU2019321583B2 (en) 2025-06-05
MX2021001761A (es) 2021-04-19
US20250057811A1 (en) 2025-02-20
JP2024083460A (ja) 2024-06-21
KR20210046708A (ko) 2021-04-28
EP3836920A4 (fr) 2022-04-13
HRP20251603T1 (hr) 2026-01-30
US12539290B2 (en) 2026-02-03
AU2019321583A1 (en) 2021-01-21
CA3104695A1 (fr) 2020-02-20
CL2021000289A1 (es) 2021-08-27
DK3836920T3 (da) 2025-12-22
IL280906A (en) 2021-04-29
TW202021583A (zh) 2020-06-16
SG11202101393PA (en) 2021-03-30
EP3836920B1 (fr) 2025-10-01
WO2020037189A1 (fr) 2020-02-20
SI3836920T1 (sl) 2026-02-27
US12005043B2 (en) 2024-06-11
AU2025226697A1 (en) 2025-09-25
UA128256C2 (uk) 2024-05-22
EP3836920A1 (fr) 2021-06-23
JP7469293B2 (ja) 2024-04-16
JP2021534189A (ja) 2021-12-09
NZ774039A (en) 2025-03-28
US20200054607A1 (en) 2020-02-20
EA202190561A1 (ru) 2021-05-26
SMT202500463T1 (it) 2026-01-12
ES3055121T3 (en) 2026-02-10
BR112020026493A2 (pt) 2021-03-23
IL325404A (en) 2026-02-01
US11260047B2 (en) 2022-03-01
PL3836920T3 (pl) 2026-02-23
TWI834708B (zh) 2024-03-11

Similar Documents

Publication Publication Date Title
EP3735685A4 (fr) Panneau d'affichage
EP3750149C0 (fr) Panneau d'affichage
MA49421A (fr) Formulations d'arn
EP3798719A4 (fr) Panneau d'affichage
EP3607587A4 (fr) Panneau d'affichage
EP3589646A4 (fr) Compositions à base de cd19 et méthodes pour l'immunothérapie
EP3926701A4 (fr) Panneau d'affichage
EP3430731A4 (fr) Architecture d'iugw
EP3836920A4 (fr) Formules d'ag10
EP3875542A4 (fr) Composition d'émulsion de silicone
EP3820490A4 (fr) Compositions d'aav
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
EP3658683A4 (fr) Découverte d'épitopes à médiation par trogocytose
EP3820980A4 (fr) Compositions d'esterquats
EP3982415A4 (fr) Panneau d'affichage
EP3482698A4 (fr) Instrument d'hémostase
EP3598705A4 (fr) Commande d'acheminement
EP3693130A4 (fr) Appareil d'usinage
EP3634276A4 (fr) Gaines d'introduction
MA53648A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase
EP3761922C0 (fr) Support d'épaule orthétique
EP3847571A4 (fr) Apprentissage d'application ido
EP3742509A4 (fr) Panneau d'affichage
EP3819231C0 (fr) Récipient d'application
EP3801488A4 (fr) Inducteurs à petites molécules d'autophagie